Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ONTOGENIC SKF 38393 TREATMENTS SENSITIZE DOPAMINE-D(1) RECEPTORS IN NEONATAL 6-OHDA-LESIONED RATS
Autore:
GONG L; KOSTRZEWA RM; BRUS R; FULLER RW; PERRY KW;
Indirizzi:
E TENNESSEE STATE UNIV,JAMES H QUILLEN COLL MED,DEPT PHARMACOL,POB 70577 JOHNSON CITY TN 37614 E TENNESSEE STATE UNIV,JAMES H QUILLEN COLL MED,DEPT PHARMACOL,POB 70577 JOHNSON CITY TN 37614 L WARYNSKI SILESIAN MED ACAD,DEPT PHARMACOL PL-41808 ZABRZE POLAND ELI LILLY & CO,LILLY RES LAB,LILLY CORP CTR INDIANAPOLIS IN 46285
Titolo Testata:
Developmental brain research
fascicolo: 1, volume: 76, anno: 1993,
pagine: 59 - 65
SICI:
0165-3806(1993)76:1<59:OS3TSD>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADENYLATE-CYCLASE ACTIVITY; 6-HYDROXYDOPAMINE TREATMENTS; POSTNATAL-DEVELOPMENT; BEHAVIORAL-RESPONSES; SELECTIVE LESIONS; D2 RECEPTORS; D1-DOPAMINE; AGONISTS; BINDING; D-1;
Keywords:
DOPAMINE; DOPAMINE-D1 RECEPTOR; 6-HYDROXYDOPAMINE; SKF 38393; ONTOGENY; SUPERSENSITIZATION; PRIMING;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
L. Gong et al., "ONTOGENIC SKF 38393 TREATMENTS SENSITIZE DOPAMINE-D(1) RECEPTORS IN NEONATAL 6-OHDA-LESIONED RATS", Developmental brain research, 76(1), 1993, pp. 59-65

Abstract

Neonatal 6-hydroxydopamine (6-OHDA) treatment of rats is associated with supersensitization of the dopamine (DA) D1 agonist induction of stereotYped and locomotor behaviors. The present study was conducted to determine whether ontogenetic treatments of these rats with the DA D1 receptor agonist, SKF 38393, would produce a maximal DA D1 receptor supersensitivity, as measured by locomotor behavior in adulthood. Rat pups were treated daily with SKF 38393-HCl (3.0 mg/kg per day, i.p.) or saline vehicle for 28 consecutive days from birth. These animals were additionally treated at 3 days after birth with 6-OHDA-HBr (100 mug, in each lateral ventricle, salt form) or its vehicle. Between 6 and 9 weeks locomotor activity or stereotyped behaviors were observed after weekly challenge doses of SKF 38393-HCl (3.0 mg/kg, i.p.). In the neonatal 6-OHDA group, successive SKF 38393 treatments produced progressively greater locomotor activity. In the group of rats treated during postnatal ontogeny with both 6-OHDA and SKF 38393 daily treatments, the first adult challenge dose of SKF 38393 produced an enhanced locomotor response, greater than that seen in other groups (P < 0.01). Subsequent SKF 38393 treatments of this group produced increasingly greater locomotor responses. SKF 38393-induced stereotyped behavioral effects were greater in the 6-OHDA-lesioned groups, whether or not SKF 38393 was administered ontogenetically. Profound reductions (> 99%) of DA and its metabolites were found in the striatum of neonatal 6-OHDA treated rats, regardless of whether SKF 38393 was co-administered ontogenetically. A marked elevation in striatal 5-HT (> 50%) accompanied the DA depletion in the striatum. These findings indicate that neonatal 6-OHDA treatment produces the expected destruction of striatal DA fibers with associated sprouting of 5-HT fibers, while repeated ontogenetic treatments of these rats with a D1 agonist produces partial sensitization of the DA D1 receptors in adulthood.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 05:03:29